Abstract
Objective:
The aim of this study was to explore the clinical role of serum interleukin-17 in patients with non-small-cell lung cancer (NSCLC).
Materials and method:
IL-17 expression and microvessel density (MVD) were measured via immunohistochemistry in 58 NSCLC tissues. Serum IL-17 and VEGF levels in NSCLC patients (n = 43) and healthy controls (n = 37) were analyzed via enzyme-linked immunosorbent assay.
Results:
Serum IL-17 was elevated and the levels positively correlated with VEGF concentration in NSCLC patients. Multivariate analyses revealed that serum IL-17 levels were an independent prognostic factor in NSCLC.
Conclusion:
IL-17 may play a role in NSCLC progression by promoting angiogenesis.
Keywords:
Angiogenesis; IL-17; VEGF; non-small cell lung cancer; prognosis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antigens, CD34 / analysis
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / blood supply
-
Carcinoma, Non-Small-Cell Lung / blood*
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Humans
-
Immunohistochemistry
-
Interleukin-17 / blood*
-
Kaplan-Meier Estimate
-
Linear Models
-
Lung Neoplasms / blood supply
-
Lung Neoplasms / blood*
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / drug therapy
-
Male
-
Microvessels / drug effects
-
Microvessels / metabolism
-
Middle Aged
-
Multivariate Analysis
-
Prognosis
-
Treatment Outcome
-
Vascular Endothelial Growth Factor A / blood*
Substances
-
Antigens, CD34
-
IL17A protein, human
-
Interleukin-17
-
Vascular Endothelial Growth Factor A